Enteral trypsin inhibitor for treatment of hemorrhagic shock
A novel enteral trypsin inhibitor is being developed to improve outcomes in hemorrhagic shock by reducing systemic inflammation and organ failure. This targeted therapy avoids complications associated with broad-spectrum inhibitors, making it suitable for bleeding patients.
Overview
The proposed solution targets the treatment of hemorrhagic shock, a critical condition characterized by systemic hypotension and organ failure. This novel approach involves the enteral delivery of a selective trypsin inhibitor to prevent the influx of pancreatic proteases into systemic circulation. By specifically inhibiting trypsin, this solution aims to reduce inflammation and improve survival outcomes while avoiding the drawbacks of broad-spectrum inhibitors that affect hemostasis, making it suitable for bleeding patients.
Technical specifications
- Selective inhibition: Targets trypsin to prevent activation of downstream proteases and inflammatory mediators.
- Enteral delivery: Administered via the gastrointestinal tract to localize treatment and minimize systemic side effects.
- Non-toxic formulation: Designed for safe use in bleeding hemorrhagic shock patients without compromising coagulation.
- Research basis: Based on extensive experimental evidence demonstrating improved outcomes with serine protease inhibition in circulatory shock.
Technology readiness level
This technology is at TRL 4, indicating that it has reached the validation stage in laboratory settings. Future validation includes animal studies simulating trauma and hemorrhagic shock to assess efficacy and safety in conditions without access to blood products.
About University of California, San Diego
UC San Diego is a comprehensive public research university in La Jolla, anchored by an integrated academic health system. On the east campus, the 23‑acre Science Research Park co‑locates corporate R&D with university programs and connects to the health sciences district, enabling daily interaction among scientists, clinicians, and companies. The Jacobs School’s Corporate Affiliates Program provides structured engagement and recruiting, while the Office of Innovation & Commercialization supports IP, licensing, and startup formation. The research enterprise is sustained by competitive federal funding, with recent awards exceeding $1.7B annually. Established commercialization pathways streamline sponsored research and help partners move from proof of concept to deployment.
delivered to your inbox.